57 - TPC-107, a next generation, HER2 selective covalent inhibitor demonstrates potent inhibition for activated mutations of HER2 while sparing EGFR inhibition.
Saved in:
| Title: | 57 - TPC-107, a next generation, HER2 selective covalent inhibitor demonstrates potent inhibition for activated mutations of HER2 while sparing EGFR inhibition. |
|---|---|
| Authors: | Oguchi, K., Irie, H., Ito, K., Fujioka, Y., Yamada, Y., Shimamura, T., Kawai, Y., Shibata, Y., Araki, H., Haruma, T., Fujioka, A., Sagara, T., Matsuo, K., Utsugi, T., Iwasawa, Y. |
| Source: | European Journal of Cancer. Dec2016 Supplement 1, Vol. 69, pS26-S26. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09598049 |
|---|---|
| DOI: | 10.1016/S0959-8049(16)32657-0 |
